Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07369089 · ClinicalTrials.gov registry record · Phase 2
Targeting Treatment-Resistant OUD With Ketamine-Assisted Mindfulness Oriented Recovery Enhancement
A Phase 2 study, sponsored by University of California, San Diego.
- Not yet
- Registry status
- Phase 2
- Development phase
- 88
- Enrollment target
NCT07369089: Clinical Trial Phase 2 study, sponsored by University of California, San Diego.
NCT07369089 is a Phase 2 study that has not yet begun recruiting, run by University of California, San Diego. The registered enrollment target is 88 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (34% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07369089, a Phase 2 study, has not yet begun recruiting, sponsored by University of California, San Diego.
- NOT YET RECRUITING
- Registry status
- Phase 2
- Development phase
- 88 participants
- Enrollment target
Study Summary
The goal of this clinical trial is to examine the usefulness of Mindfulness-Oriented Recovery Enhancement combined with Ketamine-Assisted Psychotherapy (KetaMORE) for individuals with opioid use disorder who are receiving medication treatment. The main question it aims to answer is whether individuals with opioid use disorder who receive Mindfulness-Oriented Recovery Enhancement in combination with Ketamine-Assisted Psychotherapy will demonstrate greater reductions in opioid use and craving than individuals who receive Ketamine-Assisted Psychotherapy with a non-mindfulness support group. Participants will be randomly assigned to receive either Mindfulness-Oriented Recovery Enhancement combined with Ketamine-Assisted Psychotherapy or Ketamine-Assisted Psychotherapy combined with a support group control condition. Researchers will compare these groups on days of opioid use, time to first opioid use lapse, craving, and mood, assessed using ecological momentary assessments and standardized measures collected during treatment and follow-up.
Primary Outcome
Abstinence as measured by timeline followback and triangulated by drug screen.
Interventions
- DRUG Ketamine
- BEHAVIORAL Mindfulness-Oriented Recovery Enhancement (MORE)
- BEHAVIORAL Support Group
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 88 participants |
| Start Date | 2026-02 |
| Est. Completion | 2028-04 |
| Phase | Phase 2 |
What is known before NCT07369089 opens enrollment
NCT07369089 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 88 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (34% lower).
The record links to 0 conditions, and to 3 interventions - of which Ketamine is the first listed.
NCT07369089 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07369089 about?
NCT07369089 is a clinical study titled "Targeting Treatment-Resistant OUD With Ketamine-Assisted Mindfulness Oriented Recovery Enhancement". The goal of this clinical trial is to examine the usefulness of Mindfulness-Oriented Recovery Enhancement combined with Ketamine-Assisted Psychotherapy (KetaMORE) for individuals with opioid use disorder who are receiving medication treatment. The main question it aims to answer is whether individua...
What is the current status of trial NCT07369089?
This trial is currently not yet recruiting. It is a Phase 2 study. The enrollment target is 88 participants. The study started on 2026-02. Estimated completion is 2028-04.
What interventions are being tested in trial NCT07369089?
The interventions under investigation include: Ketamine (DRUG), Mindfulness-Oriented Recovery Enhancement (MORE) (BEHAVIORAL), Support Group (BEHAVIORAL).
Who is sponsoring clinical trial NCT07369089?
This trial is sponsored by University of California, San Diego, which has 775 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07369089's enrollment target sits among peer trials
88 803rd of 2000 higher than 1,191 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03843463 · 88 participants · Phase 2
Escitalopram and Language Intervention for Subacute Aphasia
- NCT04066348 · 88 participants · Phase 2
TNF-α Treatment of Blast-Induced Tinnitus
- NCT04331704 · 88 participants · Phase 4
ANCHORS Alcohol & Sexual Health Study: UH3 Project
- NCT04536103 · 88 participants
Multi-Vendor Multi-Site Novel Accelerated MRI Relaxometry
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia